Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenlinglan Capsule is a patented Traditional Chinese Medicine (TCM) developed by Shijiazhuang Yiling Pharmaceutical. It is approved in China for the treatment of urologic diseases, specifically benign prostatic hyperplasia (BPH) and as an adjuvant therapy for prostate cancer. The formulation is designed to tonify Qi, nourish Yin, and resolve blood stasis, which are common pathological patterns in chronic prostate conditions according to TCM principles. It is composed of several botanical extracts, including Ginseng (*Panax ginseng*), Ganoderma (*Ganoderma lucidum*), and Isatis (*Isatis indigotica*).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenlinglan Capsule.